Log in

ALAFY Afyren SA EURONEXT · France

Afyren SA (ALAFY) news

Afyren SA is a public biotech or pharmaceutical company listed on EURONEXT under the ticker ALAFY, recorded under France. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Afyren SA news

We have not published a story on Afyren SA yet. When there is news, it will appear here.

Questions about Afyren SA

What is the ticker symbol of Afyren SA?

Afyren SA trades under the ticker ALAFY on EURONEXT.

Where is Afyren SA listed?

Afyren SA is listed on EURONEXT. Our directory also records these other listings: GETTEX:90N; LS:A3C29M; LSX:A3C29M.

Which country or territory is Afyren SA listed under?

Our directory records Afyren SA under France.

What does Afyren SA do?

Our directory classifies Afyren SA as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Afyren SA?

The ISIN recorded for Afyren SA is FR0014005AC9.

Does aibio.space cover Afyren SA?

aibio.space lists Afyren SA among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Afyren SA?

Companies in our directory listed in the same country and business area as Afyren SA: Euroapi SA, Inventiva SA, NFL Biosciences SA, Genfit SA, Valneva, Valbiotis SA.

Investor discussion: Afyren SA

Members talk about Afyren SA (ALAFY). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open EURONEXT:ALAFY on TradingView.

Listing details

Afyren SA is a public biotech or pharmaceutical company listed on EURONEXT under the ticker ALAFY, recorded under France. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Afyren SA
Ticker
ALAFY
Listing
EURONEXT
Country or territory
France
Business scope
Biotechnology
ISIN
FR0014005AC9
Other listed symbols
GETTEX:90N; LS:A3C29M; LSX:A3C29M
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.